Full Year 2025 loss at CytomX Therapeutics, Inc. (CTMX) was $0.15 per share GAAP. Revenue of $76.2M was reported for the full year.
Year-over-year, EPS moved down 139.5% from the $0.38 posted in Full Year 2024. That represents a 44.8% decline from the $138.1M recorded in Full Year 2024
A detailed analysis of CytomX Therapeutics, Inc.’s quarter follows shortly on AlphaStreet.
This article was generated using AlphaStreet’s proprietary financial analysis technology and reviewed by our editorial team.
The post CytomX Therapeutics, Inc. (CTMX) Reports Full Year 2025 Earnings first appeared on Alphastreet.
